| Literature DB >> 35889755 |
Douglas Ikedo Machado1, Eloiza de Oliveira Silva1, Sara Ventura1, Maria de Fatima Fernandes Vattimo1.
Abstract
Chronic kidney disease (CKD) and acute kidney injury (AKI) are global health problems that affect over 850 million people, twice the number of diabetic individuals around the world. Diabetes mellitus (DM) is known to increase the susceptibility to AKI. Plants and foods, such as curcumin, are traditionally used as treatments for various diseases due to its wide range of bioactive compounds that exert antioxidative, anti-inflammatory, antimicrobial and anticancer properties. The aim of this study is to evaluate the effect of curcumin in diabetic rats with AKI. Adult male Wistar rats, weighing between 250 and 290 g, were randomized into four groups: Citrate (citrate buffer, i.v., single dose, on Day 1 of the protocol); DM (streptozotocin (STZ), 65 mg/k, single dose, i.v., on Day 1); DM + I/R (DM rats that, on Day 26, had the renal pedicle clamped for 30 min on both sides); DM + I/R + Curcumin (DM + I/R rats submitted to curcumin treatment). Results showed that IR worsened renal function and oxidative stress in DM rats, but the DM + IR + Curcumin group showed an increase in inulin clearance and a decrease in serum creatinine and in NGAL, in addition to an improvement in renal hemodynamics. These effects were accompanied by a reduction in oxidative and nitrosative metabolites and an increase in the thiol antioxidant reserve when curcumin was administered to the DM + IR group.Entities:
Keywords: curcumin; diabetes; ischemia/reperfusion
Mesh:
Substances:
Year: 2022 PMID: 35889755 PMCID: PMC9323852 DOI: 10.3390/nu14142798
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Monitoring of blood glucose.
| Groups |
| Initial—48 h | 1st Week | 2nd Week | 3rd Week | 4th Week |
|---|---|---|---|---|---|---|
| Citrate | 5 | 86.7± 3.7 | 89.7 ± 8.3 | 97.3 ± 10.7 | 86.2 ± 11.6 | 95.7 ± 7.7 |
| DM | 5 | 374.6 ± 51.3 a | 389.3 ± 76.2 a | 389.7 ± 91.2 a | 380.7 ± 84.0 a | 390.0 ± 58.0 a |
| DM + I/R | 5 | 342.6 ± 57.4 a | 342.0 ± 67.9 a | 334.7 ± 37.5 a | 374.6 ± 78.1 a | 345.9 ± 57.2 a |
| DM + I/R + Curcumin | 5 | 330.7 ± 63.3 a | 349.4 ± 43.3 a | 346.4 ± 55.6 a | 335.1 ± 66.6 a | 311.3 ± 66.5 a |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Body weight.
| Groups |
| 1st Week | 2nd Week | 3rd Week | 4th Week |
|---|---|---|---|---|---|
| Citrate | 5 | 278 ± 57 | 306 ± 60 | 343 ± 49 | 366 ± 54 |
| DM | 5 | 281 ± 9 | 274 ± 10 | 272 ± 13 a | 247 ± 16 a |
| DM + I/R | 5 | 216 ± 22 a,b | 233 ± 35 a | 243 ± 42 a | 281 ± 17 a,b |
| DM + I/R + Curcumin | 5 | 258 ± 14 | 284 ± 23 | 279 ± 18 a | 309 ± 14 a |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Kidney weight and body weight/animal weight ratio.
| Groups |
| Kidney Weight (g) | Kidney Weight/Animal Weight |
|---|---|---|---|
| Citrate | 5 | 1.3 ± 0.1 | 0.3 ± 0.1 |
| DM | 5 | 1.9 ± 0.2 a | 0.6 ± 0.04 a |
| DM + I/R | 5 | 1.8 ± 0.4 a | 0.5 ± 0.1 a |
| DM + I/R + Curcumin | 5 | 1.4 ± 0.2 | 0.5 ± 0.1 a,b |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Food and water intake.
| Groups |
| Food (g) | Water (mL) |
|---|---|---|---|
| Citrate | 5 | 23.0 ± 1.7 | 22.5 ± 2.9 |
| DM | 5 | 35.4 ± 0.9 a | 88.0 ± 13.0 a |
| DM + I/R | 5 | 19.8 ± 9.4 a,b | 35.0 ± 20.0 b |
| DM + I/R + Curcumin | 5 | 20.7 ± 8.3 a,b | 59.2 ± 15.7 a,b |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Renal function.
| Groups |
| 24 h Urinary Flow | Serum Creatinine | Inulin Clearance | Urinary NGAL |
|---|---|---|---|---|---|
| Citrate | 5 | 0.011 ± 0.003 | 0.28 ± 0.05 | 0.91 ± 0.26 | 41.41 |
| DM | 5 | 0.056 ± 0.010 a | 1.08 ± 0.14 a | 0.58 ± 0.04 a | 57.25 |
| DM + I/R | 5 | 0.011 ± 0.005 b | 2.76 ± 0.67 a,b | 0.15 ± 0.06 a,b | 142.42 a,b |
| DM + I/R + Curcumina | 5 | 0.025 ± 0.005 a,b,c | 0.93 ± 0.12 a,c | 0.44 ± 0.11 a | 81.35 c |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Renal hemodynamics.
| Groups |
| Heart Rate | Mean Arterial Pressure (mmHg) | Renal Blood Flow (mL/min) | Renal Vascular Resistance |
|---|---|---|---|---|---|
| Citrate | 5 | 460 ± 56 | 97 ± 9 | 8.1 ± 1.3 | 11.3 ± 1.9 |
| DM | 5 | 471 ± 23 | 118 ± 26 | 4.8 ± 0.4 a | 26.7 ± 6.8 a |
| DM + I/R | 5 | 500 ± 41 | 95 ± 5 | 2.2 ± 0.3 a,b | 43.5 ± 5.7 a,b |
| DM + I/R + Curcumin | 5 | 522 ± 29 | 99 ± 12 | 5.1 ± 1.1 a,c | 20.9 ± 2.0 a,c |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.
Oxidative profile.
| Groups |
| Urinary Peroxides | Lipid Peroxidation | Urinary Nitrate | Renal Tissue Thiols (nmol/mg of Total Protein) |
|---|---|---|---|---|---|
| Citrate | 5 | 0.90 ± 0.12 | 0.29 ± 0.05 | 22.01 ± 5.84 | 25.98 ± 2.87 |
| DM | 5 | 3.59 ± 0.38 a | 10.45 ± 0.46 a | 51.70 ± 10.45 a | 15.52 ± 2.45 a |
| DM + I/R | 5 | 5.85 ± 0.25 a,b | 23.29 ± 2.30 a,b | 165.83 ±13.56 a,b | 11.01 ± 2.16 a,b |
| DM + I/R + Curcumin | 5 | 1.80 ± 0.48 a,b,c | 9.13 ± 2.40 a,c | 60.51 ± 10.87 a,c | 19.86 ± 2.77 a,c |
ap < 0.05 versus Citrate; b p < 0.05 versus DM; c p < 0.05 versus DM + I/R.